August 2012
-
Discovery Laboratories has announced that it will switch its focus from Surfaxin lucinactant intratracheal suspension product to development of its Aerosurf aerosolized KL4 surfactant for the treatment of respiratory distress syndrome in premature infants. The… Read more . . .
-
In a letter from the FDA to Sunovion dated March 12, 2015, the agency informed the company that all postmarketing requirements and commitments specified after the 2005 approval of the Xopenex HFA levalbuterol MDI have… Read more . . .
-
The FDA has listed PARI’s Kitabis Pak in the Orange Book as a therapeutic equivalent of Novartis’s TOBI tobramycin inhalation solution with an AN rating, PARI has announced. Kitabis Pak, tobramycin inhalation solution packaged with… Read more . . .
-
California-based biopharmaceutical company Ruthigen and inhaled drug developer Pulmatrix have announced a definitive merger agreement under whose terms Pulmatrix will become a wholly-owned subsidiary of Ruthigen. According to the announcement, conversion of Pulmatrix’s outstanding debt… Read more . . .
-
The Indian patent office has revoked a Boehringer Ingelheim patent for Spiriva on grounds that “applicant have failed to establish any technical advancement or any economic significance of the compound Tiotropium bromide monohydrate over the… Read more . . .
-
Copley Scientific has announced the availability of new firmware for its TPK 2000 Critical Flow Controller that allows the instrument to be used for leak testing of cascade impactors without the need for any additional… Read more . . .
-
Sandoz has launched its AirFluSal Forspiro salmeterol/fluticasone DPI for the treatment of asthma and COPD in Portugal and Ireland, the company said. AirFluSal is now available in twelve European countries, South Korea, and Mexico. The… Read more . . .
-
2014 Pat Burnell New Investigator Award winner Abhinav Kumar of King’s College London will collaborate with Inhalation Sciences AB onsite in Stockholm, Sweden, the company has announced. The joint research project will explore the use… Read more . . .
-
Swedish CDMO Recipharm has announced the appointment of Thomas Beck to the new senior role of Vice President Quality Management, effective April 1, 2015. Beck has been Head of Quality Control and Assurance at Recipharm… Read more . . .
-
AmpliPhi BioSciences (formerly Targeted Genetics) has announced that it has raised approximately $13,000,000 in a private placement financing that it will use for three development programs. The company’s lead candidate, AmpliPhage-001, is an inhaled bacteriophage… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland